Experienced in Autosomal Recessive Hypotrichosis

Louise Provencher

Public Health Branch, 
Quebec, QC, CA 
Experienced in Autosomal Recessive Hypotrichosis
Public Health Branch, 
Quebec, QC, CA 
OverviewLocationsClinical Research

Overview

Louise Provencher practices in Quebec, Canada. Ms. Provencher is rated as an Experienced expert by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Breast Cancer, Autosomal Recessive Hypotrichosis, Febrile Neutropenia, Fibroadenoma, and Mastectomy.

Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Autosomal Recessive Hypotrichosis.

Gender
Female

Locations

Public Health Branch, Quebec, QC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Large-scale Longitudinal Oncology Registry
A Large-scale Longitudinal Oncology Registry
Enrollment Status: Suspended
Publish Date: February 04, 2025
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
Real-World Data Study in HER2+ Metastatic Breast Cancer Patients in Third-Line Therapy
Real-World Data Study in HER2+ Metastatic Breast Cancer Patients in Third-Line Therapy
Enrollment Status: Completed
Publish Date: October 07, 2021
Intervention Type: Other
A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)
A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)
Enrollment Status: Completed
Publish Date: April 03, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 4 Less Clinical Trials

91 Total Publications

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Provencher's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile